Due to one previous report outlining NAION risk and semaglutide use, the study authors relay that, in response, the American Academy of Ophthalmology has issued a press release for physicians and patients: The Academy has not recommended that patients stop using semaglutide, but rather, that patients experiencing vision loss while taking semaglutide should stop the drug and contact the physician prescribing the medication. 1 They reflect that, because of the association of semaglutide with temporary worsening of diabetic retinopathy, the increased incidence of diabetic macular edema and the concern that rapid correction of hyperglycemia could induce papillitis, physicians prescribing this medication to their patients with type II diabetes should consider a drug regimen that more gradually lowers the HbA1C level. 1 In an invited commentary on the research, also published by JAMA Ophthalmology , commentators point to a few different related studies that have already taken place, detailing their methods and outcomes
We assess your medical history based on lab work and body analysis, past attempts at weight loss, your goals, and also your current lifestyle
Seven Phase 3 trials are expected to complete in 2026, with regulatory submission likely following shortly after
Of course, your body produces GLP-1 naturally after you eat, but Ozempic and other similar medications are more reliable forms of the same hormone your body makes, Dr
In chronic conditions such as type 2 diabetes and obesity, treatments that fit into everyday routines may be easier to stay on
PIONEER 18 enrolled patients with early, established, and advanced T2D from a global population
